Synergy Pharmaceuticals Named to NASDAQ Global Select Market
NEW YORK -- January 2, 2014
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced listing of the
company’s common stock has been transferred to the NASDAQ Global Select
Market, the highest of the three market tiers at NASDAQ. Listing on the NASDAQ
Global Select Market is reserved for companies that meet the highest
quantitative and qualitative listing standards, reflecting their demonstrated
commitments to leadership and good governance.
NASDAQ-listed companies are classified under three listing tiers: NASDAQ
Global Select Market, NASDAQ Global Market, and NASDAQ Capital Market. Synergy
common shares previously traded on the NASDAQ Capital Market and will continue
to trade today on the NASDAQ Global Select Market under the ticker symbol
Synergy Pharmaceuticals Inc. is a biotechnology company focused on the
research and development of novel drugs for the treatment of gastrointestinal
(GI) diseases and disorders. Synergy has discovered proprietary analogs of the
human GI hormone, uroguanylin, the natural agonist for the intestinal
guanylate cyclase-C (GC-C) receptor. Both Synergy’s lead GC-C agonist,
plecanatide, and next-generation GC-C agonist, SP-333, mimic uroguanylin’s
natural functions by binding to and activating the GC-C receptor in the GI
tract to stimulate fluid and transit required for normal digestion.
Plecanatide is in phase 3 clinical trials for chronic idiopathic constipation
and a phase 2b study for irritable bowel syndrome with constipation. SP-333 is
in phase 2 development for opioid-induced constipation and is also being
explored for ulcerative colitis. For more information please visit
Synergy Pharmaceuticals Inc.
Gem Gokmen, Office: 212-584-7610
Bernard Denoyer, Office: 212-297-0020
Press spacebar to pause and continue. Press esc to stop.